Rank |
Status |
Study |
1 |
Recruiting
|
Turnover of Antigen Specific Lymphocytes After Immunization With the Yellow Fever Vaccine
Condition: |
Yellow Fever |
Interventions: |
Biological: Yellow fever vaccine; Biological: Yellow fever vaccine and D20 water |
Outcome Measures: |
To evaluate the life span and decay curve of effector CD8 T cells after immunization with 17D yellow fever vaccine; To evaluate the rate of homeostatic turnover of memory CD8 T cells after immunization with 17D yellow fever vaccine |
|
2 |
Not yet recruiting
|
Safety and Immunogenicity of Q Fever Vaccine
Condition: |
Q Fever |
Intervention: |
Biological: Q fever Vaccine |
Outcome Measures: |
Change in Immunogenicity; Percentage of subjects with symptoms following Q fever vaccination; Percentage of subjects with erythema following Q fever vaccination along with severity and association with vaccination; Percentage of subjects with induration following Q fever vaccination along with severity and association with vaccination; Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination; Percentage of subjects with symptoms following Q fever skin test antigen; Percentage of subjects with erythema following Q fever skin test antigen along with severity and association with skin test antigen; Percentage of subjects with induration following Q fever skin test antigen along with severity and association with skin test antigen; Percentage of subjects with each AE, system organ class of AE, severity, and association with skin test antigen |
|
3 |
Recruiting
|
Respiratory Physiology in Children With Febrile Seizures.
Conditions: |
Febrile Illness in Children; Seizures, Febrile |
Intervention: |
|
Outcome Measures: |
Change of transcutaneous pCO2 per change of body temperature [mmHg/degree C]; Change of respiratory rate per change of body temperature [1/sec * degree C]; Change of transcutaneous pCO2 per change of respiratory rate [mmHg * sec] |
|
4 |
Recruiting
|
Etiologies of Fever Among Adults in Dar es Salaam
Condition: |
Acute Febrile Illnesses |
Intervention: |
|
Outcome Measures: |
Proportion of patients with each disease among all febrile patients, overall and stratified by HIV status; Proportion of febrile patients with acute respiratory infection infected with a certain respiratory pathogen, compared to the proportion of healthy controls infected with the same pathogen. |
|
5 |
Recruiting
|
Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma
Condition: |
Soft Tissue Sarcoma |
Intervention: |
Radiation: Hyperthermia and Proton Beam |
Outcome Measures: |
To evaluate safety of hyperthermia and proton beam treatment in unresectable soft tissue sarcomas; To evaluate the local response to hyperthermia and proton beam therapy as a preoperative regimen for unresectable soft tissue sarcomaLocal control |
|
6 |
Not yet recruiting
|
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
Conditions: |
Febrile Neutropenia; Hematological Malignancy |
Intervention: |
Drug: Discontinuation of imipenem-cilastatin or meropenem |
Outcome Measures: |
The percentage of patients with failed treatment; All-cause mortality; Infection-related mortality; The length of hospitalization in days; Unexpected re-admission other than for planned chemotherapy or other elective treatment.; The recurrence of fever within 24 hours after discontinuation of antibiotic therapy.; The total number of febrile episodes during neutropenia; Time to defervescence; Antibiotic or antifungal treatment within 30days after discharge other than standard antibiotic prophylaxis.; Incidence and prevalence of Clostridium difficile infection; Incidence and prevalence of liver and kidney dysfunction; Candida spp. colonization in (surveillance) cultures; Cost of antimicrobial therapy per admission; MASCC-score; The percentage of patients with mucositis and positive blood cultures or short treatment failure.; Bacterial resistance in blood cultures and surveillance cultures (including minimal inhibitory concentrations (MIC)). |
|
7 |
Recruiting
|
Human Immune Responses to The Yellow Fever Virus Vaccine
Condition: |
Yellow Fever |
Intervention: |
Biological: Yellow fever vaccine |
Outcome Measures: |
1. Isolation and characterization of yellow fever vaccine (YFV-17D) specific adaptive immune responses: characterize the magnitude and quality of YFV specific T cell responses, antibody secreting cells and memory B cells.; Determine the signatures of innate immune responses: cytokines, chemokines, dendritic cells and microarray analyses on peripheral blood mononuclear cells |
|
8 |
Unknown †
|
A Screening Strategy for Q Fever Among Pregnant Women
Condition: |
Q Fever |
Intervention: |
Other: screening |
Outcome Measures: |
obstetric or maternal complications in Q fever positive women; course of infection in pregnant women; the accuracy of the diagnostic tests used for screening; placentitis; costs |
|
9 |
Recruiting
|
Pilot Study of a Catheter-based Ultrasound Hyperthermia System
Conditions: |
Cervical Cancer; Prostate Cancer |
Interventions: |
Procedure: Hyperthermia; Radiation: HDR brachytherapy |
Outcome Measures: |
Evaluate the safety and tolerability of interstitial and endocavitary ultrasound hyperthermia therapy; Evaluate the feasibility, defined as being able to administer hyperthermia at a specified temperature range and thermal dose.; Characterize the interstitial and endocavitary ultrasound heating technology by describing the thermal parameters including attainable temperature and thermal dose distribution and duration at the tumor treatment region. |
|
10 |
Unknown †
|
West Indies-French Guiana Dengue Study
Conditions: |
Fever; Dengue |
Interventions: |
Other: biological sample collection; Other: quality of life questionnaire EuroQol® |
Outcome Measures: |
Occurrence, during follow-up (for 12 weeks following symptom onset), of shock, internal bleeding, failure of one or several organs or systems (brain, heart, lung, liver, kidney, clotting system), or death.; Onset of dengue hemorrhagic fever (WHO criteria). Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms. |
|
11 |
Recruiting
|
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)
Conditions: |
Visceral Leishmaniasis; Human African Trypanosomiasis; Enteric Fever; Melioidosis; Brucellosis; Leptospirosis; Relapsing Fever; Rickettsial Diseases; HIV; Tuberculosis; Malaria; Amoebic Liver Abscess |
Interventions: |
Device: rk28 ICT; Device: IT LEISH (rK39); Device: Immunochromatographic HAT test; Device: HAT Serostrip; Device: Card Agglutination Trypanosoma Test (CATT)-10; Device: Typhidot M; Device: S. typhi IgM/IgG; Device: Test-it Typhoid IgM; Device: Test-it Leptospirosis IgM; Device: Leptospira IgG/IgM |
Outcome Measures: |
Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs); Identification of clinical and laboratory diagnostic indicators; Identification of reliable Rapid Diagnostic Tests (RDTs); Predictive values of RDTs; Cost-effectiveness of the diagnostic tests |
|
12 |
Recruiting
|
Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever
Conditions: |
Enteric Fever; Typhoid Fever |
Interventions: |
Drug: Ceftriaxone; Drug: Gatifloxacin |
Outcome Measures: |
Rate of treatment failure; Time to fever clearance; S.typhi or S.paratyphi carriage; Number of adverse events; Household transmission |
|
13 |
Recruiting
|
Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage
Condition: |
Fever |
Interventions: |
Drug: Intravenous Ibuprofen; Drug: Acetaminophen (Standard of Care) |
Outcome Measures: |
Fever Burden; Inflammatory Markers; Cost analysis; Bleeding Incidence |
|
14 |
Recruiting
|
Reliability of Subjective Assessment of Fever by Parents and Health Care Providers in Children and Adolescents
Condition: |
FEVER |
Intervention: |
|
Outcome Measure: |
subjective assessment of fever by both parents and medical personnel will be unreliable |
|
15 |
Recruiting
|
A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer
Condition: |
Ovarian Cancer |
Intervention: |
Device: ThermalCore Hyperthermia System |
Outcome Measures: |
Organ toxicity; Time To Progression of Disease |
|
16 |
Recruiting
|
Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
Condition: |
Breast Cancer |
Intervention: |
Drug: ThermoDox in combination with Microwave Hyperthermia (heat) |
Outcome Measures: |
To determine the bioequivalence of ThermoDox when used with hyperthermia among patients with RCW breast cancer.; To determine efficacy of ThermoDox in combination with Hyperthermia; To evaluate the safety of ThermoDox in combination with Hyperthermia |
|
17 |
Recruiting
|
Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer
Condition: |
Rectal Cancer |
Interventions: |
Radiation: Radiotherapy; Procedure: Hyperthermia; Drug: 5-Fluorouracil; Drug: Capecitabine; Drug: Oxaliplatin |
Outcome Measures: |
Feasibility rate (i.e. rate of patients not experiencing dose-limiting toxicity [DLT]); Number of hyperthermia applications by patient; Local progression-free survival; Distant metastasis-free survival; Overall survival; Response rate; Rate of R0-resections; Rate of acute and late toxicity |
|
18 |
Unknown †
|
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
Condition: |
Pancreatic Cancer |
Interventions: |
Biological: recombinant interferon alfa; Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: hyperthermia treatment |
Outcome Measures: |
Tumor response; Toxicity; Survival; Changes in quality of life; Conversion of inoperable tumors to operable; Changes in cellular and cytokine immune function |
|
19 |
Recruiting
|
Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Gastrointestinal Tract Cancer Liver Metastasis
Condition: |
The Patients With Unresectable Chemoresistant Multiple Liver Metastasis From Colorectal Cancer |
Intervention: |
Radiation: Combined hyperthermia and radiation therapy |
Outcome Measures: |
Time to local tumor progression after combined hyperthermia and RT; Objective response rate of combined hyperthermia and RT; Change from baseline quality of life at 3 months; Local tumor progression free survival rate after combined hyperthermia and RT; Adverse event after combined hyperthermia and RT.; Overall survival rate after combined hyperthermia and RT |
|
20 |
Unknown †
|
Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
Condition: |
Fever |
Interventions: |
Drug: Ibuprofen suppository; Drug: Ibuprofen Suspension |
Outcome Measures: |
Maximal change in temperature during the 4-hour period after enrollment.; Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at 4h. Decrement in fever at each time point, and the area under the temperature (versus time) curve. Proportion of patients with temperature < 38 at 4 hours. |
|